11-keto-β-Boswellic Acid
(Synonyms: 11-酮基-BETA-乳香酸,11-oxo-β-Boswellic acid,KBA) 目录号 : GC10821A 5-LO inhibitor
Cas No.:17019-92-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 35.8 μM: inhibits MCF-7 (human breast adenocarcinoma) [1].
37.9 μM: blocks A2780 (cis-platin resistant ovarian cancer cells) [1].
11-keto-β-Boswellic Acid, known as KBA, is a naturally occurring pentacyclic triterpene isolated from the gum resin of the tree Boswellia serrata. KBA is non-redox, specific leukotriene synthesis inhibitors through the inhibition of 5-lipoxygenase (5-LOX) which has anti-arthritic and anti-inflammatory activities. 5-LOX catalyzes essential fatty acids substrates into leukotrienes and a variety of other biologically active products. KBA is a novel activator of nuclear factor erythroid-2-related factor 2 (Nrf2), which protects against cerebral ischemic injury.
In vitro: KBA, concentration dependently, decreased the formation of leukotriene B4 and the synthesis of all 5-LOX products from endogenous arachidonic acid in rat peritoneal neutrophils. In contrast, KBA exerted no remarkable effects on the 12-lipoxygenase and cyclooxygenase activities. [2].
In vivo: Adult male Sprague–Dawley rats were injected KAB intraperitoneally at a dose of 25 mg/kg for 48 hours. KAB remarkably decreased infarct volumes as well as apoptotic cells at 1 h, and then increased neurologic scores when applied 48 h. Moreover, posttreatment with KBA induced the decrease of malondialdehyde levels and the increase of protein Nrf2 and heme oxygenase-1 expression in brain tissues, indicating that the Nrf2/HO-1 pathway was involved in the neuroprotection of KBA against oxidative stress-induced ischemic injury [3].
References:
[1]. Csuk, R., Barthel-Niesen, A., Barthel, A., Schffer, R., & Al-Harrasi, A. 11-Keto-boswellic acid derived amides and monodesmosidic saponins induce apoptosis in breast and cervical cancers cells. European Journal of Medicinal Chemistry. 2015; 100: 98-105.
[2]. Safayhi, H., Mack, T. H. O. M. A. S., Sabieraj, J. O. A. C. H. I. M., Anazodo, M. I., Subramanian, L. R., & Ammon, H. P. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. Journal of Pharmacology and Experimental Therapeutics. 1992; 261(3):1143-1146.
[3]. Ding, Y., Chen, M., Wang, M., Li, Y., & Wen, A. Posttreatment with 11-Keto-β-Boswellic Acid Ameliorates Cerebral Ischemia–Reperfusion Injury: Nrf2/HO-1 Pathway as a Potential Mechanism. Molecular Neurobiology. 2014; 52(3): 1430-1439.
Cas No. | 17019-92-0 | SDF | |
别名 | 11-酮基-BETA-乳香酸,11-oxo-β-Boswellic acid,KBA | ||
化学名 | (3α,4β)-3-hydroxy-11-oxo-urs-12-en-23-oic acid | ||
Canonical SMILES | O=C1C=C2[C@](CC[C@]3(C)C2[C@@H](C)[C@H](C)CC3)(C)[C@]4(C)CCC5[C@@](C)(C(O)=O)[C@H](O)CC[C@]5(C)C41 | ||
分子式 | C30H46O4 | 分子量 | 470.4 |
溶解度 | ≤5mg/ml in ethanol;25mg/ml in DMSO;25mg/ml in dimethyl formamide | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1259 mL | 10.6293 mL | 21.2585 mL |
5 mM | 0.4252 mL | 2.1259 mL | 4.2517 mL |
10 mM | 0.2126 mL | 1.0629 mL | 2.1259 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。